Status:
COMPLETED
Descriptive Study in Patients Treated With Vimovo™, Including Registration of the Physicians' Prescribing Patterns
Lead Sponsor:
AstraZeneca
Conditions:
Osteoarthritis
Rheumatoid Arthritis
Eligibility:
All Genders
18+ years
Brief Summary
The most common pain-relievers used by patients with rheumatic disorders are called non-steroidal anti-inflammatory drugs (NSAIDs). These drugs are effective and well documented, but they can cause ul...
Detailed Description
European study in patients with osteoarthritis, rheumatoid arthritis, or ankylosing spondylitis at gastrointestinal risk: A retrospective, non-interventional study of Vimovo™ prescribing patterns
Eligibility Criteria
Inclusion
- Diagnosis of arthritic disorder (osteoarthritis, rheumatoid arthritis or ankylosing spondylitis) Risk for developing gastrointestinal ulcer Already prescribed Vimovo
Exclusion
- Participation in any interventional drug study at the time Vimovo™ was prescribed
- Patients started on Vimovo during the first 3 months after country-specific launch date
- Patients started on Vimovo after the study site is initiated (in order to avoid influence on prescribing decision and recruitment)
Key Trial Info
Start Date :
January 1 2012
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
March 1 2014
Estimated Enrollment :
2000 Patients enrolled
Trial Details
Trial ID
NCT01511926
Start Date
January 1 2012
End Date
March 1 2014
Last Update
March 10 2015
Active Locations (96)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Aalst, Belgium
2
Research Site
Dilbeek, Belgium
3
Research Site
Erembodegem, Belgium
4
Research Site
Genk, Belgium